Daraxonrasib Pancreatic Cancer Results: A Historic Breakthrough

Original Article by Lisa Jarvis | Bloomberg | 15 April 2026

Daraxonrasib pancreatic cancer trial results show that Revolution Medicines' new therapy is doubling survival rates and reshaping oncology.

Daraxonrasib pancreatic cancer trial results show that Revolution Medicines’ new therapy is doubling survival rates and reshaping oncology.

Subscription Required

You must be a subscriber to access all of this content.

Already a subscriber? Log in here

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.